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ecurrent neuroendocrine adenoma of the mid-
le ear: A case report
n cas d’adénome amphicrine récidivant de l’oreille moyenne
The authors report the case of a 27-year-old man  with recurrent
euroendocrine adenoma of the left middle ear. The tympa-
um was explored via a posterior approach due to suspicion of
holesteatoma of the middle ear, allowing resection of tumour tis-
ue during this surgical procedure. Histological examination was  in
avour of neuroendocrine adenoma.
Six years later, the patient reported onset of left-sided hear-
ng loss. Audiogram demonstrated unilateral left-sided conductive
earing loss estimated at 40 db HL. Otoscopic examination revealed
 whitish retrotympanic mass. Computed tomography of the
etrous temporal bone demonstrated a round tumour occupying
he epitympanic recess and mesotympanum with signs suggestive
f ossicular lysis (Fig. 1).
Exploration of the tympanum via a posterior approach allowed
esection of two recurrent tumours in the additus-ad-antrum and
esotympanum. Partial lysis of the incudostapedial joint was
bserved, but the ossicular chain nevertheless remained mobile
nd continuous. The bony implantation base of the lesion was
rilled and the ossicular chain was preserved.
Histological examination demonstrated 2 sites of recurrence
f neuroendocrine adenoma measuring 7 mm and 2 mm,  with
o signs of cytonuclear atypia. An immunohistochemical study
emonstrated labelling of the cells with synaptophysin antibody
nd chromogranin (Fig. 2).
Fig. 2. Demonstration of chromogranin (a) and synaptophysin (b) immuno
http://dx.doi.org/10.1016/j.anorl.2014.02.004
879-7296/© 2014 Elsevier Masson SAS. All rights reserved.Fig. 1. Computed tomography visualizing a tumour around the long process of the
incus with opaciﬁed mastoid air cells.
An audiometric gain of 10 db HL was observed one month after
the surgical procedure. At 3-year follow-up, the patient did not
present any recurrence and the audiometric gain was maintained.
Neuroendocrine adenoma of the middle ear (NAME) is a very
rare benign tumour, ﬁrst described in 1976 [1]. About ﬁfty cases
have subsequently been reported in the literature [2]. The mean agehistochemical markers in favour of neuroendocrine differentiation.
at diagnosis is 45 years [2]. The most frequent complaint is onset of
unilateral conductive hearing loss [2–4]. Other possible symptoms
are a feeling of ear fullness, earache, vertigo, tinnitus, superinfec-
tion, otorrhagia and facial paralysis [2–4]. Computed tomography
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eveals a non-speciﬁc tumour without osteolysis, localized in the
iddle ear, intimately related to the ossicular chain and associated
ith opaciﬁed mastoid air cells. The lesion can spread to the mas-
oid, external auditory canal and Eustachian tube [2]. Treatment
onsists of surgical resection [2,3,5]. The recurrence is 18% to 22%
2,3]. Preservation of the ossicle chain, when involved, increases
he risk of recurrence [2].
NAME is a benign tumour presenting double adenomatous and
euroendocrine on differentiation [4,5]. Neuroendocrine differen-
iation is demonstrated on immunohistochemistry by labelling
f tumour cells by chromogranin A and synaptophysin [2,4].
enign neuroendocrine tumours have been described by various
erms: middle ear adenoma, amphicrine, carcinoid or adenocarci-
oid tumour. These various terms actually correspond to a single
istological entity, but presenting varying degrees of glandular
nd neuroendocrine differentiation. The term carcinoid tumour of
he middle ear was deﬁned by analogy with intestinal or bron-
hopulmonary carcinoid tumours. Carcinoid tumour is the most
ggressive form of middle ear adenoma [5].isclosure of interest
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